Compare Becton Dickinson and Co (BDX) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Solaredge Technologies Inc — how do they compare? Becton Dickinson and Co trades at $155.18 (market cap $41.51B), while Solaredge Technologies Inc trades at $54.39 (market cap $3.38B). The key difference: Becton Dickinson and Co is far larger — about 12.3× Solaredge Technologies Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| BDX | SEDG | |
|---|---|---|
Market Cap | $41.51B | $3.38B |
Sector | Health | Technology |
52-Week High | $185.39 | $78.51 |
52-Week Low | $135.49 | $24.42 |
Enterprise Value | $57.97B | $3.31B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
SolarEdge Technologies (SEDG) trades at $52.13, down 5.53% amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with a -28.56% net margin and -72.5% ROE, though recent quarters saw earnings beats. Revenue declined from $3.1B in 2022 to $1.18B in 2025, reflecting solar market challenges. Analyst sentiment is cautious with a $35.56 consensus target below current price, while technical indicators show bearish momentum with key support at $49.
SEDG faces significant headwinds with persistent losses and declining revenue, though operational cash flow turned positive in 2025. Investment opportunity exists if solar demand recovers, but risks include intense competition, policy uncertainty, and high debt levels. The stock remains speculative with substantial downside risk to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
